Company news

Arvinas, Inc. news in 2020

Arvinas, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares

December 27, 2020

Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock

December 14, 2020

Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110

December 13, 2020

Arvinas, Inc. Announces Proposed Offering of Common Stock

December 13, 2020

Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs

December 10, 2020

Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 4, 2020

Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins

October 13, 2020

Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit

October 5, 2020

Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference

September 3, 2020

Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference

August 6, 2020

Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 3, 2020

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

June 28, 2020

Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference

June 16, 2020

Arvinas Appoints Linda Bain to its Board of Directors

June 10, 2020

Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference

June 4, 2020

Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer

May 28, 2020

Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders

May 19, 2020

Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer

May 12, 2020

Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update

April 27, 2020

Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic

April 12, 2020

Arvinas to Present at the American Society of Clinical Oncology Annual Meeting

March 30, 2020

Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

March 15, 2020

Decks in 2020